Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
287 GBX | -5.59% | +6.30% | +1.41% |
05:10pm | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
04:07pm | European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.41% | 3.24B | |
+26.11% | 653B | |
+27.00% | 556B | |
-6.47% | 354B | |
+20.14% | 331B | |
+3.85% | 296B | |
+12.88% | 233B | |
+5.59% | 201B | |
-9.65% | 193B | |
-6.30% | 144B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED China : Secures Licensing Rights to Epizyme's Cancer Drug in Greater China